Loading
Oral decitabine-cedazuridine is a pill version of the hypomethylating chemotherapy that, since May 2026, lets older AML patients take their whole venetoclax regimen at home.
Cedazuridine inhibits cytidine deaminase in the gut and liver so oral decitabine achieves IV-equivalent exposure. Approved for MDS/CMML (2020). On 13 May 2026 the FDA approved Inqovi with venetoclax for newly diagnosed AML in adults ≥75 or with comorbidities precluding intensive induction, based on ASCERTAIN-V (CR 41.6%, median time to CR 2 months), the first all-oral hypomethylating regimen for AML.
Decitabine incorporates into DNA and traps DNMT1; cedazuridine protects it from first-pass deamination.
1.Cedazuridine blocks cytidine deaminase in the gut and liver
Source: www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute. Doses are for orientation; the current label governs.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Inqovi is oral decitabine; Medicare contractors generally treat it as Part D rather than under the oral anticancer Part B benefit because cedazuridine has no injectable equivalent.
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA932. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
MDS/CMML
With venetoclax in newly diagnosed unfit AML source
| Region | Year | Indication |
|---|---|---|
| US | 2020 | MDS and CMML |
| US | 2026 | Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V) |
| EU | 2023 | EU brand Inaqovi |
| Adverse event |
|---|
| Neutropenia and febrile neutropenia Class effect with venetoclax; counts monitored each cycle |
| Nausea, fatigue Common, mostly grade 1-2 |
Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Decitabine + cedazuridine" OR ABSTRACT:"Decitabine + cedazuridine" OR TITLE:"oral" OR ABSTRACT:"oral" OR TITLE:"Inqovi" OR ABSTRACT:"Inqovi" OR TITLE:"Decitabine-cedazuridine" OR ABSTRACT:"Decitabine-cedazuridine" OR TITLE:"Oral decitabine" OR ABSTRACT:"Oral decitabine" OR TITLE:"Cedazuridine" OR ABSTRACT:"Cedazuridine") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Decitabine + cedazuridine (oral), not a curated reading list.
Shares Higher-risk myelodysplastic syndromes, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Decitabine, Higher-risk myelodysplastic syndromes, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS).
Shares Decitabine, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax, Myelodysplastic syndromes / neoplasms (MDS).
Shares Venetoclax + hypomethylating agent, Shorter venetoclax courses in unfit AML, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Venetoclax.
Shares Venetoclax + hypomethylating agent, Shorter venetoclax courses in unfit AML, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Venetoclax.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Epigenetic progenitor theory: cancer without a first mutation, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.